About

Michael Bell has served as Guardant Health's Chief Financial Officer since January 2021.

He most recently served as the Chief Financial Officer of CareDx, Inc., a precision medicine company focused on transplantation, from April 2017 to December 2020. From January 2016 to March 2017, Mr. Bell served as Chief Financial Officer of Metabiota, Inc., a company that develops and sells risk analytics products focused on infectious disease. From May 2012 to January 2016, he served as Chief Financial Officer of Singulex, Inc., a clinical diagnostics company. Prior to that, he held leadership and executive positions within Novartis, including with Novartis Diagnostics, where he served as Chief Financial Officer from 2011 to 2012 and Senior Director, Global Head of Finance from 2008 to 2011.

Mr. Bell also previously worked for several years in public accounting with both Ernst & Young and Deloitte, UK. He holds a Bachelor of Science in Mathematics with Computing from the University of Leicester in the United Kingdom and is a Fellow of the Institute of Chartered Accountants in England & Wales.

Roles

Guardant Health, Inc.
Chief Financial Officer · Current role
2021–present
CareDx, Inc.
Chief Financial Officer · Precision medicine company focused on transplantation.
2017-2020
Metabiota, Inc.
Chief Financial Officer
2016-2017
Singulex, Inc.
Chief Financial Officer · Clinical diagnostics company.
2012-2016
Novartis (Novartis Diagnostics)
Chief Financial Officer; Senior Director, Global Head of Finance · CFO of Novartis Diagnostics 2011-2012; Senior Director, Global Head of Finance 2008-2011.
2008-2012
Ernst & Young and Deloitte, UK
Public accounting roles
CareDx
Chief Financial Officer
2017-2020
Singulex
Chief Financial Officer and SVP
2012-2016
Novartis Diagnostics
Chief Financial Officer

Also at Guardant Health, Inc.

Related

See how VectorShift works for your firm

Request Demo